290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant:…
jwood@krftwrk.caNovember 14, 2018
On January 13th, 2017 CARE™ faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology…
jwood@krftwrk.caJanuary 23, 2017
SABCS 2016. P5-16-17. Population based long-term outcomes of pathologic complete response after neoadjuvant chemotherapy in…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. P4-22-13. Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. S1-03. First results from the multicenter phase III DATA study comparing 3 versus…
jwood@krftwrk.caDecember 21, 2016
Biologic therapy has revolutionized the treatment of IBD and improved patient outcomes drastically. Many of…
jwood@krftwrk.caDecember 13, 2016
ESMO 2016. LBA14_PR. FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole…
jwood@krftwrk.caNovember 9, 2016
Metastatic Breast Cancer ASCO 2016. Abstract 525. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM)…
jwood@krftwrk.caJune 29, 2016
